TRCT
MLYS icon

Tower Research Capital (TRC)’s Mineralys Therapeutics MLYS Stock Holding History

Tower Research Capital (TRC)’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$215K Buy
7,923
+7,403
+1,424% +$217K 0.01% 1561
2025
Q4 		$18.9K Sell
520
-2,851
-85% -$114K ﹤0.01% 3137
2025
Q3 		$128K Buy
3,371
+622
+23% +$13.5K ﹤0.01% 1807
2025
Q2 		$37.2K Buy
2,749
+1,575
+134% +$22.8K ﹤0.01% 3226
2025
Q1 		$18.6K Buy
1,174
+169
+17% +$1.94K ﹤0.01% 3042
2024
Q4 		$12.4K Sell
1,005
-1,669
-62% -$21.8K ﹤0.01% 3621
2024
Q3 		$32.4K Sell
2,674
-697
-21% -$8.44K ﹤0.01% 2961
2024
Q2 		$39.4K Buy
3,371
+3,076
+1,043% +$38.7K ﹤0.01% 3278
2024
Q1 		$3.81K Sell
295
-2,584
-90% -$31.9K ﹤0.01% 4787
2023
Q4 		$24.8K Sell
2,879
-7,181
-71% -$56.4K ﹤0.01% 3527
2023
Q3 		$95.7K Buy
10,060
+9,718
+2,842% +$127K ﹤0.01% 2010
2023
Q2 		$5.83K Sell
342
-1,156
-77% -$17.3K ﹤0.01% 4784
2023
Q1 		$23K Buy
+1,498
New +$25.2K ﹤0.01% 3289

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Tower Research Capital (TRC)'s MLYS Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Mineralys Therapeutics (MLYS) stake by 1,424% in Q1 2026, buying an estimated $217K and bringing the position to 7,923 shares worth $215K. The position accounts for 0.01% of the portfolio, ranked #1561.

Tower Research Capital (TRC) first reported a position in MLYS in Q1 2023 and has held it in 13 quarters since. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Tower Research Capital (TRC) held 7,923 shares of Mineralys Therapeutics worth $215K as of Q1 2026.
  • Tower Research Capital (TRC) bought 7,403 Mineralys Therapeutics shares in Q1 2026, an estimated $217K.
  • Mineralys Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1561 holding.
  • Tower Research Capital (TRC) first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.